Dr. Kent Holtorf and the Integrative Peptide Protocol

Note: This is part 4 of 4 where I map the major thinkers in CIRS and mold-related illness: what each one believes, where each one is strong, and where each one breaks down.

Introduction: I argued that the four major camps of CIRS treatment aren’t actually contradicting each other. Each one is answering the same question in a different way:

Where is the illness?

Part One: Does the Shoemaker Protocol Work? This post looks at the camp that addresses the question through scientific inquiry.
Part Two: Addressing the needs of the CIRS patient. We took a look at Dr. Neil Nathan and Dr. Jill Crista, two clinicians who focus on the most sensitive patients.
Part Three: Mycotoxins and the immune response. Examining the diagnostic method of Dr. Andrew Campbell, a clinician who looks at the immune system’s antibody response.
Part Four: This post takes a look at Dr. Kent Holtorf and his argument that mold illness isn’t actually about the mold.

The first three camps, for all their differences, share the assumption that the mold did something to the patient:

• Dr. Ritchie Shoemaker measures the inflammation it triggered.
• Dr. Neil Nathan and Dr. Jill Crista manage the sensitivity and colonies it left behind.
• Dr. Andrew Campbell measures the antibodies it provoked.

All of them treat the toxin as the prime mover.

Dr. Kent Holtorf says they’re all looking in the wrong place. That instead of the toxin, we should be examining the patient. We’ll dive deep into exactly what this means in today’s post.

*Note: this blog was written by me, Mark Volmer. All spelling mistakes, misquotes, errors, and omissions are my own doing. It is not AI generated. *

Expert Recap: Dr. Kent Holtorf and Integrative Peptides

Dr. Kent Holtorf does not believe mold is the cause of the immune dysregulation behind mold illness, or CIRS. Instead, Dr. Holtorf claims that the immune dysregulation was already present, and mold is only the trigger that caused CIRS. His treatment focuses on correcting the immune system, so it can clear out toxins and get rid of the inflammation on its own. He uses peptides to nudge cells back towards normal function, instead of forcing them.

His claims are worth examination as many ring true. However, the basis of Dr. Holtorf’s claims are limited trials that he has controlled. He also owns the product line that his patients are directed to purchase from. Finally, his attacks on the Shoemaker protocol do not hold up under scrutiny. So while he has some valid points, they are not backed up by the same rigorous scientific investigations that Dr. Shoemaker has provided for his protocol.

Where Dr. Holtorf says the illness lives

Recall our original question: Where is the illness?

Dr. Holtorf’s answer… It’s in the immune system, not the mold. He says that CIRS is a pre-existing immune dysfunction that the patient was already carrying. The mycotoxin exposure was merely the tipping point that shoved an already-fragile system over the edge.

Holtorf’s argument explains the question every mold clinician eventually confronts: Why does one person get so sick from a building when others are untouched?

Dr. Shoemaker blames genetics (the HLA anomaly).

Dr. Holtorf blames the susceptible patient’s immune system. He believes the patient’s immune system was already compromised, and the mold simply exposed and amplified what was there.

He uses a recurring patient, “Sarah,” to illustrate his point. Sarah has been compliantly following the Shoemaker protocol for years, but her TGF-β1 biomarker is still stubbornly high and she is still sick. Dr. Holtorf’s diagnosis of Sarah’s situation is that while the Shoemaker protocol was chasing biomarkers, her profoundly dysfunctional immune system went untouched. His metaphor: you can’t mop a flooded basement while the dam upriver is still broken.

Note: this stubbornly elevated TGF beta 1 marker is something I see clinically quite often. More on what I think is going on in this case in an upcoming blog where I lay out my treatment philosophy.

Holtorf’s Take on What’s Driving the Illness

I’ll concede that Dr. Holtorf theory of what’s driving CIRS is genuinely more mechanistically sophisticated than the other camps. He describes the immune dysfunction as four interlocking failures:

T-cell exhaustion

T-cells are the part of the adaptive immune system. The adaptive immune system creates specific antibodies for invaders, so you won’t catch the same virus or bacteria twice. This is why (hopefully) you’ve never had chicken pox again. The job of T-cells is to recognize and respond to the invaders. Ongoing mycotoxin exposure, plus the reactivation of latent viruses results in T-cell exhaustion.

Holtorf argues that past exposures to virus/bacteria/fungi have exhasuted your T cells. When this occurs, a critical arm of adaptive immunity goes functionally dark.

No new T-cells

New T-cells are trained in the thymus. Mycotoxins are directly toxic to the thymus, so as the thymus shrinks, the body is not able to create new T-cells to counter new threats. As a result, the current T-cells are exhausted and there are no new ones coming in to replace them.

The immune system seesaw

Part of the immune system is suppressed, leaving the you unable to control viruses or clear toxins. Another part of the immune system goes into overdrive, resulting in hypersensitivity and inflammation. Holtorf argues this single imbalance accounts for most CIRS symptoms.

Suppression of natural killer cells

Natural killer (NK) cells are the rapid-response force against viruses and malignant cells in the innate immune system. Even a tiny amount of mycotoxins can suppress their activity.

This is a coherent and biologically literate explanation about why a subset of patients stay sick. It takes the immune dysfunction that Shoemaker’s model acknowledges but treats as downstream, and promotes it to the lead role.

Holtorf’s Treatment: restore the regulator (don’t manage the toxins)

If the problem is a broken immune system, it follows that the immune system should be repaired first. A restored immune system can then clear the toxins, control the infections, and quell the inflammation on its own. Dr. Kent Holtorf calls this an “inside-out” model, and his tool of choice is peptides. Peptides are short amino acid chains that act as signalling molecules, nudging cells back toward normal function rather than forcing them.

His protocol, the unfortunately-named Holtorf Updated Peptide Protocol for the Rapid Treatment of CIRS (HUPPRTOC), is sequenced as follows:

1. Restore thymus function
2. Reverse T-cell exhaustion
3. Heal the gut and blood-brain barriers
4. Restore mitochondrial energy
5. Let downstream resolution take care of itself

He uses the following peptides:

• Thymic peptides:
  • Vilon,
  • Thymogen,
  • Thymogen Alpha-1,
  • TB4 fragment
  • These are used to rebuild T-cell production and rebalance the immune  seesaw. They are claimed to directly inhibit TGF-β1.
• Barrier and gut-brain peptides:
  • BPC-157 for mucosal and blood-brain barrier repair;
  • KPV, an MSH fragment, for mast-cell inhibition and antimicrobial action.
• Pineal peptides:
  • Epitalon,
  • Pinealon
  • Used to reset the neuroendocrine axis, sleep, and circadian rhythm.
• Mitochondrial peptides:
  • MOTS-c,
  • SS-31,
  • Humanin
  • Used to restore the cellular energy that detoxification and immune function both require.

Dr. Kent Holtorf vs Dr. Shoemaker

The treatment Dr. Kent Holtorf proposed is in direct opposition to the Shoemaker protocol.

Binders:

Cholestyramine (CSM) is the approved binder for the Shoemaker protocol. Dr. Kent Holtorf calls CSM “marginally beneficial, fraught with numerous side effects, and poorly tolerated,”. He notes that it is often prescribed for years without meaningful improvement, and refers to it as a passive “mopping up” that never addresses why the body can’t clear toxins itself. He replaces binding with peptides that offer cellular protection, in addition to a mitochondrial-enabled natural detox.

TGF-β1:

Dr. Shoemaker uses losartan, which is a repurposed blood-pressure drug to lower TGF-β1. It is introduced late in the protocol and for a limited window of time. Dr. Holtorf’s peptides target TGF-β1 directly and from the outset. I will note that most Shoemaker practitioners are no longer using losartan. Most are now relying on high doses of vasoactive intestinal polypeptide (VIP) to lower TGF beta 1.

VIP:

Holtorf is not a fan of VIP. In fact, he is directly opposed to using it. I’m going to dedicate the entire next section of this blog to Holtorf vs VIP.

Holtorf’s claim against VIP

VIP (vasoactive intestinal peptide) is the final step of the Shoemaker protocol, and the therapy patients work toward for months. Dr. Holtorf argues VIP is not just unnecessary but also dangerous. He claims that in the high-TGF-β1 inflammatory state of CIRS, VIP becomes pro-inflammatory, induces T-cell exhaustion, suppresses NK function, and raises cancer risk. Dr. Holtorf says that any symptom relief experienced by patients is a mask over “progressive immune deterioration.”

I use VIP clinically and carefully in appropriate patients. This is done after removal from exposure, MARCoNS have been cleared, and VCS tests are passed. I believe Dr. Holtorf’s claim about VIP is the weakest link in an otherwise interesting argument.

Here’s the problem: the claim is asserted, not demonstrated. Dr. Holtorf presents the claim that VIP is a cancer risk and contributes to immune deterioration. However, he offers no controlled human data showing that VIP therapy, when administered correctly in the Shoemaker protocol, produces worse outcomes, T-cell exhaustion, or cancer in real CIRS patients.

Like everything in the Shoemaker protocol, sequencing and timing is tremendously important. This could not be more true in the context of VIP. I would agree with Holtorf insofar as VIP administered when a patient is still in exposure is dangerous. I’ve seen a lot of adverse reactions to VIP when a patient is still in exposure. But when the Shoemaker protocol is followed correctly, VIP is the last step. This is because the preceding steps have removed the exposure and lowered the inflammation, making VIP use safe.

Proper adherence to the Shoemaker protocol ensures that VIP is not administered if the patient is in a state of seriously elevated TGF-β1; note: TGF-β1 is often highly elevated when one is in exposure. Dr. Holtorf isn’t wrong – VIP should not be used to paper over an active, unaddressed inflammatory state. However, his criticism of VIP is not of VIP itself, but of the improper timing of its use.

When a safety allegation this serious is thrown at Shoemaker’s signature therapy, the burden is on the accuser to show the harm in the population being treated. That burden hasn’t been met here. In fact, the overwhelming majority of my patients experience tremendous benefit from VIP use. It’s often THE intervention that moves the needle firmly towards recovery.

Where Dr. Holtorf’s claims break more broadly

Dr. Holtorf’s claim about VIP is one instance of a pattern that runs through his whole framework.

His certainty outruns the evidence.

I don’t love the language used by the Holtorf camp: “revolutionary,” “paradigm shift,” “rapid,” “superior efficacy,” “exceptional safety profile.”

It’s not that I’m against any of those adjectives. But let’s remember what he’s using these claims towards: peptides. BPC-157, TB4, KPV, the thymic and pineal bioregulators, are largely unapproved, research-status compounds with limited human trial data for these specific uses. “Exceptional safety profile” is asserted, but it is not shown with long-term human safety studies.

The longevity evidence is thin and narrowly sourced.

The supporting data for the pineal and thymic peptides leans heavily on Russian bioregulator research from the Khavinson/Anisimov groups in the early 2000s. This work exists, but it has not been independently replicated at scale in the West, and it is treated cautiously by the broader scientific community. The headline claims of reversing biological age by years, and dramatic telomere lengthening come from Dr. Holtorf’s own ongoing, uncontrolled programs, not from randomized controlled trials.

He doesn’t transcend biomarkers, he swaps them.

Dr. Holtorf criticizes the reliability of Dr. Shoemaker’s biomarkers, then offers NK cell activity and an expanded coagulation panel as more reliable alternatives. He’s still measuring; he just prefers his own instruments. Let’s remember that the Shoemaker biomarkers on their own are not specific to CIRS. But when grouped together, they become highly sensitive and specific to CIRS. That’s been flushed out in the research. We cannot say the same about Holtorf’s panel.

The protocol is a product line.

Halfway through Holtorf’s document that lays out the science, the focus turns into longevity marketing and direct promotion of his own peptide company, his clinic, and specific named products. I’m not suggesting the science is invented to sell the peptides. But when the person describing the disease, defining the protocol, and selling the compounds is the same person, a patient should know where the science ends and the profit begins. The relentless optimism of the narrative makes more sense considering there are products to sell.

What I take from Dr. Kent Holtorf

I think Holtorf is right about the biology and overconfident about the cure. He has correctly identified the thing the Shoemaker model underweights: a real, mechanistically describable immune dysfunction that helps explain why a specific population: the reactive, the chronically infected, the long-haul non-responders; stays sick no matter how faithfully they run the standard protocol.

That population is precisely who walks into my clinic. And several of his tools are genuinely useful for them: BPC-157 for barrier repair, KPV for mast-cell and antimicrobial action, the mitochondrial peptides for the energy floor. Each of these have plausible mechanisms and are genuinely helpful.

Where I get off the train is the leap from “these tools help” to “this is a paradigm shift.” The peptides are an addition to my toolkit for difficult cases, not a wholesale substitute for an objective, validated, sequenced framework. The “rapid” and “superior” and “replaces VIP” claims run ahead of the data. And the commercial machinery surrounding the protocol is a reason for caution.

So, I borrow the tools and I distrust the certainty. For a non-responder who has stalled on the standard approach, peptides aimed at the immune and mitochondrial terrain can be exactly what’s needed. They’re used as a careful adjunct, with the same objective markers I’d use anyway, and without the promise that we’ve found the one true cause of the disease.